Comparative Pharmacology
Head-to-head clinical analysis: CEFAZOLIN SODIUM versus RESPORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFAZOLIN SODIUM versus RESPORAL.
CEFAZOLIN SODIUM vs RESPORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP1a, PBP1b, PBP2a, PBP2b, PBP2x, PBP3, and PBP4, thereby preventing cross-linking of peptidoglycan chains. This leads to cell lysis and death.
RESPORAL contains theophylline, a methylxanthine that inhibits phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cAMP and cGMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation and anti-inflammatory effects.
1-2 g IV/IM every 8 hours; maximum 12 g/day for severe infections.
2 mg orally twice daily
None Documented
None Documented
Approximately 1.8 hours (range 1.2-2.2 h) in normal renal function; prolonged in renal impairment (up to 30-40 h in ESRD)
Terminal half-life is 12 hours (range 10-14 h), supporting twice-daily dosing in most patients.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); minimal biliary (1-2%); fecal (<1%)
Renal excretion accounts for 70% of elimination (30% unchanged), biliary/fecal 20%, and 10% metabolized.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic